Comparative Pharmacology
Head-to-head clinical analysis: ANDROID F versus DANOCRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID F versus DANOCRINE.
ANDROID-F vs DANOCRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
None Documented
None Documented
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Category C
Category C
Androgen/Estrogen Combination
Androgen/Antigonadotropin